NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Novartis' acute myeloid leukemia drug Rydapt (midostaurin) in combination with chemotherapy alongside Invivoscribe Technologies' LeukoStrat CDx FLT3 Mutation Assay to identify patients who can receive the drug.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.